Company News
-
Sep 10, 2019Clover Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis
-
May 7, 2019Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
-
Aug 1, 2018Clover Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China
-
Jun 18, 2018Clover Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
-
Jan 23, 2018Clover selects GE’s FlexFactory biomanufacturing platform for its new production facility in China
-
Dec 22, 2017Clover Receives CFDA Approval to Initiate Clinical Trials in China with Etanercept Biosimilar Candidate SCB-808
-
Dec 14, 2017Clover Completes RMB 62.8 Million Series A Financing
-
Oct 15, 2016Clover Scientists’ Discovery Featured on the Cover of The Journal of Immunology
-
Feb 19, 2016Clover initiates GLP studies on SCB-313 (Trail-Trimer) at National Shanghai Center for New Drug Safety Evaluation and Research.
-
Nov 13, 2015Clover filed IND with CFDA for SCB-808, a ready-for-injection biosimilar of blockbuster anti-TNF biologic, Enbrel (etanercept)
-
Oct 23, 2015Clover initiated gp120-Trimer (SCB-703) AIDS vaccine study
